TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has recently entered into a non-exclusive License and Supply Agreement with Lonza. This partnership aims to make CleanCap mRNA capping technologies more widely available as the demand for mRNA continues to soar in various industries.
Under the terms of the agreement, TriLink will provide Lonza with its patented CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, and CleanCap AU cap analogs. These cutting-edge technologies will be utilized in Lonza’s global mRNA development and manufacturing services, catering to projects ranging from pre-clinical stages through Phase III programs.
CleanCap technology is known for its exceptional efficiency, with over 95% capping efficiency. It offers a streamlined approach to mRNA production processes, outperforming traditional capping methods.
Drew Burch, the President of Nucleic Acid Production at TriLink, expressed his excitement about the partnership, stating, “CleanCap technology is accelerating programs from discovery to the clinic through enhanced mRNA function, simplified manufacturing, and maximized capped material yield. We are thrilled to offer our innovative capping solutions to Lonza and its customers.”
TriLink’s CleanCap capping technology has been a game-changer since its launch in 2017, becoming a staple in the production of approved mRNA and saRNA vaccines. In May 2023, TriLink unveiled its most advanced CleanCap analog, CleanCap M6, which demonstrated a remarkable increase in mRNA expression by more than 30% compared to enzymatic capping methods.
In summary, the collaboration between TriLink and Lonza is set to revolutionize the utilization of CleanCap technology in mRNA applications. This partnership holds great promise for the future of mRNA-based innovations in various industries.
(Business Wire)